Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track.
Amgen, Inc. CEO Robert Bradway has described the company’s biosimilars portfolio as “performing well and in line with our expectations” during a Q1 results call, with impending biosimilar launches expected to provide a substantial boost to this segment of its business.
The charge is set to be led by the US launch of Humira biosimilar Amjevita (adalimumab-atto). Amjevita – known as Amgevtia in other regions – is expected to be the first Humira biosimilar to launch in the US on 31 January 2023
Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.
Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.
With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
